Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | Updates on ropeginterferon in MPNs

Jean-Jacques Kiladjian • 22 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms Hydroxyurea Ropeginterferon alfa-2b

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shares some updates on the role of ropeginterferon alfa-2b in the treatment of myeloproliferative neoplasms (MPNs), highlighting the efficacy of this agent in comparison to best available therapy (BAT). Prof. Kiladjian further discusses some results from a six-year follow-up study comparing the use of ropeginterferon versus BAT. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.

More from Jean-Jacques Kiladjian

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
2:31
The growing role of combination approaches in MF & agents being explored
Jean-Jacques Kiladjian • 9 Oct 2023
4:35
The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs
Jean-Jacques Kiladjian • 13 Jun 2023
2:14
Ruxolitinib combinations in patients with myelofibrosis
Jean-Jacques Kiladjian • 26 Apr 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals